Six Aging Clocks Agreed on Insilico's AI Drug. The Hard Endpoint Is Still Missing.
Insilico Medicine moved an AI-designed drug from target to preclinical candidate in 18 months. In September it reported biological-age reduction across six independent proteomic clocks, then opened a longevity toolkit and a vaccine program. What is missing is the endpoint investors actually price.